Inactive Instrument

Conformis, Inc.

Equities

CFMS

US20717E2000

Medical Equipment, Supplies & Distribution

Conformis, Inc. Provides Second Quarter Revenue Guidance for the Financial Year Ending December 31, 2023

May 08, 2023 at 01:05 pm

Conformis, Inc. provided second quarter revenue guidance for the financial year ending December 31, 2023. For the period, the company expects second quarter product revenue to be in the range of $11.0 million to $13.0 million.

Latest news about Conformis, Inc.

Conformis, Inc. Announces Board Changes	05/09/23	CI
Conformis, Inc.(NasdaqCM:CFMS) dropped from NASDAQ Composite Index	05/09/23	CI
Restor3D, Inc. completed the acquisition of Conformis, Inc. from shareholders.	04/09/23	CI
Conformis, Inc.(NasdaqCM:CFMS) dropped from S&P TMI Index	01/09/23	CI
Conformis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/08/23	CI
Earnings Flash (CFMS) CONFORMIS Posts Q2 Revenue $13M	02/08/23	MT
Sector Update: Health Care Stocks Lower Late Friday	23/06/23	MT
Sector Update: Health Care	23/06/23	MT
Top Midday Gainers	23/06/23	MT
Global markets live: 3M Company, Meta, Moderna, Carmax, Shell...	23/06/23
It just won't go away	23/06/23
Sector Update: Health Care Stocks Decline Premarket Friday	23/06/23	MT
Wall Street Set to Open Lower Ahead of June's Flash PMI; Oil Prices Drop Sharply	23/06/23	MT
Sector Update: Health Care	23/06/23	MT
US Futures Trend Lower Premarket Friday Ahead of June's Flash PMI	23/06/23	MT
Top Premarket Gainers	23/06/23	MT
ConforMIS Agrees to be Acquired by restor3d	23/06/23	MT
Restor3D, Inc. entered into a definitive merger agreement to acquire Conformis, Inc. from shareholders for $17.9 million.	21/06/23	CI
Conformis, Inc. Announces Resignation of Robert S. Howe as Treasurer, Effective June 9, 2023	19/05/23	CI
Conformis, Inc. Announces Chief Financial Officer Changes, Effective June 9, 2023	19/05/23	CI
Conformis, Inc. Announces Board Changes	10/05/23	CI
Oppenheimer Downgrades ConforMIS to Perform From Outperform, Removes $6 Price Target	09/05/23	MT
Transcript : Conformis, Inc., Q1 2023 Earnings Call, May 08, 2023	08/05/23
Conformis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI
Earnings Flash (CFMS) CONFORMIS Reports Q1 Revenue $12.8M, vs. Street Est of $12.6M	08/05/23	MT

Chart Conformis, Inc.

Duration

Period

More charts

Company Profile

Conformis, Inc. is a medical technology company. The Company is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The Company offers knee replacement products and knee replacement products. The Company's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The Company owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Medical Devices & Implants

	1st Jan change	Capi.
STRYKER CORPORATION	+11.67%	126B
SMITH & NEPHEW PLC	-4.96%	11.27B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+3.22%	9.12B
GLAUKOS CORPORATION	+39.27%	5.61B
INSPIRE MEDICAL SYSTEMS, INC.	-22.29%	4.75B
AXONICS, INC.	+8.74%	3.45B
ENOVIS CORPORATION	-5.83%	2.89B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-13.32%	2.07B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-6.99%	2.05B

Medical Devices & Implants